CBDRA60
Phase 1- Indications
- Post acute COVID-19 syndrome, Severe acute respiratory syndrome
Company intelligence / Profile preview
Anewsha Therapeutics
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Anewsha Therapeutics is a small private therapeutics company associated with development of CBDRA60, an investigational combination of cannabidiol and Gigartina red algae formulated as a sublingual tablet. The company appears to be focused on immune-modulating and antiviral-supportive approaches in COVID-19 and post-acute sequelae of SARS-CoV-2 infection. Publicly available evidence for the company is sparse, with the clearest primary-source footprint coming from a ClinicalTrials.gov record naming Anewsha Therapeutics Inc. as sponsor of a not-yet-recruiting study. Based on the limited public record, the company seems to be an early-stage healthcare/biotech entity rather than a commercial-stage pharmaceutical business.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculePeptides
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Michigan Biologics Consulting
Beyond the preview
Go deeper on Anewsha Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Anewsha Therapeutics.